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The major sources of microbe-based biotech-
nology products (MBPs) released into the
environment today are commercial Bacillus
thuringiensis (BT) products that are derived
from similarly produced, large-scale, sporula-
tion-phase cultures of B. thuringiensis sub-
species, mainly, israelensis (Bti) for targeting
the larval stage of blood-sucking flies
(Dipterans) and kurstaki (Btk) for targeting
foliage-eating larvae of moths (Lepidoptera)
(1,2). The combined production of these BT
products exceeds 500 metric tons annually in
North America (3). From the point of view of
homogeneity, these biopesticides (also known
as bioinsecticides, biorationale pesticides, or
biological control agents) are very complex
(2). However, whether in dry (powdered) or
liquid states, they are very similar because
they are essentially mixtures of culture ingre-
dients that include, in increasing order of
their mass, variable amounts of minerals,
extracellular nucleic acid, a large spectrum of
proteins (mostly sporulation phase-speciﬁc),
and viable spores, often exceeding 1012/L of
BT product (2,4,5). The liquid versions of
both Bti- and Btk-derived commercial BT
products can be easily fractionated by differ-
ential centrifugation to yield similar-sized par-
ticulate fractions containing > 99.9% of the
spores and also the proteinaceous component
made up of both regular and irregular amor-
phic structures (2). This proteinaceous mater-
ial cannot be quantitatively separated from
spores and other culture debris. The regular
variably sized aggregates are predominantly
those that are often referred to as crystal tox-
ins (1,6). These structures make up the bulk
of the mature parasporal inclusion body (PIB)
matrix and contain most of the δ -endotoxins
precursors (also any partially processed or
degraded forms) encoded by speciﬁc cry genes
(1,6). The PIBs are known to be coformed
during sporulation within the sporangium or
spore-mother cell, but exact details concern-
ing molecular and cellular events in their for-
mation and maturation have not been
obtained. 
The PIB components of Bti (spherical)
and Btk (bipyramidal) are uniquely different
in shape and in protein composition, albeit
we note in this study [and also noted by
Beegle and Yamamoto (1) and Seligy and
Rancourt (5)] that their size and amount in
both cases can be highly variable. There is
also a considerable amount of poorly deﬁned,
amorphic, proteinaceous material that we
suggest originated from various stages of the
culture process, including trace amounts
(usually < 1% of viable spore count) of
enzymes such as β -lactamase, proteases, and
cuboidal-like crystals, the latter whose com-
position and cytotoxic effects are unknown
(1,2,5). Our previous analyses (2–5,7) sug-
gest that most of these structures are the like-
ly sources of the prominent polypeptide size
classes (60–67 kDa and 132–137 kDa) relat-
ed to different maturation stages and classes
of different δ -endotoxins, which essentially
deﬁne the subspecies in the B. thuringiensis
classification system and attribute target
organism’s toxicity (1,6). 
Through the years, the research and
development emphasis on B. thuringiensis-
mediated insecticidal activity has focused
almost exclusively on the different types of δ -
endotoxins, which are uniquely encoded by
over 60 cry genes (6). However, only a few of
these δ -endotoxins have been actually studied
in any critical detail. Also, in comparison, the
B. thuringiensis spores and other components
that are obviously present in BT products
have been greatly underinvestigated either as
bona ﬁde components of “active ingredient”
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Most contemporary bioinsecticides are derived from scaled-up cultures of Bacillus thuringiensis
subspecies israelensis (Bti) and kurstaki (Btk), whose particulate fractions contain mostly B.
thuringiensis spores (> 1012/L) and proteinaceous aggregates, including crystal-like parasporal
inclusion bodies (PIB). Based on concerns over relatedness to B. cereus-group pathogens, we con-
ducted extensive testing of B. thuringiensis (BT) products and their subfractions using seven
human cell types. The Bti/Btk products generated nonspecific cytotoxicities involving loss in
bioreduction, cell rounding, blebbing and detachment, degradation of immunodetectable pro-
teins, and cytolysis. Their threshold dose (Dt ≈  5 × 10–14% BT product/target cell) equated to a
single spore and a target cell half-life (tLD50) of approximately 16 hr. At Dts > 104, the tLD50
rapidly shifted to < 4 hr; with antibiotic present, no component, including PIB-related δ -endo-
toxins, was cytolytic up to an equivalent of approximately 109 Dt. The cytolytic agent(s) within
the Bti/Btk-vegetative cell exoprotein (VCP) pool is an early spore outgrowth product identical to
that of B. cereus and acting possibly by arresting protein synthesis. No cytolytic effects were seen
with VCP from B. subtilis and Escherichia coli. These data, including recent epidemiologic work
indicate that spore-containing BT products have an inherent capacity to lyse human cells in free
and interactive forms and may also act as immune sensitizers. To critically impact at the whole
body level, the exposure outcome would have to be an uncontrolled infection arising from intake
of Btk/Bti spores. For humans, such a condition would be rare, arising possibly in equally rare
exposure scenarios involving large doses of spores and individuals with weak or impaired microbe-
clearance capacities and/or immune response systems. Key words: biopesticides, bioreduction, cell
death, cytolytic factors, endotoxin, immunodetection, immune sensitization, 35S-methionine, veg-
etative cells. Environ Health Perspect 108:919–930 (2000). [Online 18 August 2000]
http://ehpnet1.niehs.nih.gov/docs/2000/108p919-930tayabali/abstract.html
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Articlesor as potential hazards (1,2–5,7). In side-by-
side tests using insect cell assays similar to
those claimed to be effective in the elucida-
tion of B. thuringiensis δ -endotoxins (8–11),
we demonstrated that the most toxic con-
stituent of whole BT products is actually
spore related (4,7). Depending on dose
expressed either in international units or per-
cent of BT per target cell, and temperature
(23°C to 37°C), we found that the spore-
induced response time, measured as target cell
half-life (tLD50), was entirely consistent with
estimates of pest mortality derived in ﬁeld and
laboratory tests with larvae (7). Because the
fastest response time, measured in terms of
tLD50, was < 4 hr at 37 ± 3°C (the optimum
Btk or Bti spore outgrowth temperature) and
because 5–20% of these spores remained
viable, even under the harshest pH and tem-
perature conditions used by the human body
defense system (2), these spores have the
potential to survive and also to propagate in
an in vivo mammalian environment. 
Our concern over the virulence potential
of these organisms focuses on evidence that
demonstrates the close genetic similarities
between B. thuringiensis organisms and
B.cereus and B.anthracis pathogens (12,13)
reports on putative infections arising from
various B. thuringiensis subspecies (14–20),
and recent epidemiologic evidence of
Bernstein et al. (3) showing the occurrence of
immune sensitization from use of commercial
BT products in the control of lepidopteran
pests of agricultural crops. In this agriculture-
related exposure study, the immune sensitivi-
ty displayed by migrant workers was directed
mainly at spore and vegetative cell compo-
nents, suggesting that the δ -endotoxin com-
ponents, at least as presented in BT products,
were not very reactive, basically masked as
compared to other cellular components.
Therefore, as a baseline approach to clarify at
least some of the concerns raised here, we
conducted a detailed comparative study of the
exposure effects of contemporary commercial
BT products using several bioindicator sys-
tems with a variety of cells derived from dif-
ferent human and animal tissues. 
In the present study, we summarize a
large body of these cell and molecular biology
experiments and illustrate key ﬁndings with
data derived mainly from a human cell line
(HT29) that has been used to model intesti-
nal epithelial cell differentiation and effects of
chemotoxins and microbial pathogens
(21–34). Because contemporary Bti/Btk BT
products are complex in composition, we
carried out a series of experiments using sub-
fractions of BT products (2,3) to determine
which ones were the most biologically active
and hence might potentially represent the
biggest hazard. These experiments included
analysis of BT product derivatives that could
arise essentially by a form of biotransforma-
tion as in the parlance of chemical toxicants.
In this context, the BT product ingredients
are transformed either through proteolysis of
the proteinaceous moieties, particularly the
pro-δ -endotoxins associated with PIB and
amorphic structures, and/or through the pro-
duction of spore-derived vegetative cells and
their exo-products and products made after-
ward during a second generation of sporula-
tion-phase activity. In reference to Bti/Btk
vegetative cell exoproteins (VCPs) we also
investigated their cytotoxic properties using
35S-methionine in experiments to measure
effects on human cell biosynthesis and VCPs
derived from strains of B. cereus, B. subtilis,
and Escherichia coli.
Materials and Methods
Human target cells. The American Type
Culture Collection (ATCC; Rockville, MD,
USA) supplied the colonic epithelial cells
(Caco-2, lot F-10803, and HT-29, lot F-
12101), liver cells (Chang, lot F-11873, and
Hep-G2 , F-11225), and human blood deriv-
atives, HL-60 (F-11917) and K-562 (F-
11533). Mature erythrocytes were collected as
previously described (3). Conditions for
short- and long-term cultures are described
elsewhere (4,7,29,30). Brieﬂy, cells were cul-
tured using Dulbecco’s Modified Eagles
Medium (DMEM) with 25 mM glucose, 2
mM glutamine, 10% (v/v) fetal bovine serum
(FBS), and 50 g/mL gentamicin in either T25
or T80 ﬂasks (Life Technologies, Burlington,
Ontario, Canada). Treatments with BT prod-
ucts and their subfractions were conducted in
6-, 48-, and 96-well plates at 37°C. Effects of
dose, head volume over monolayers, and api-
cal–basal surface exposure were assessed using
6- and 12-well culture plates with porous
membranes for transfeeding (0.22 µm pore
size; Costar, Cambridge, MA). Monolayers (2
× 106 cells/cm2 ) were established 1 day
before testing. All cell types were rinsed with
DMEM (2 times) to remove antibiotic
immediately before treatments. For scanning
electron microscopy (SEM) analyses, cell
monolayers were established on glass cover-
slips. Following exposure, cells were fixed
with 4% (v/v) glutaraldehyde in 100 mM
sodium cacodylate (pH 7.2) at room temper-
ature (RT), post-ﬁxed with 1% (w/v) osmi-
um tetroxide in 100 mM sodium cacodylate,
and dehydrated with an ethanol series.
Samples were dried in a critical point drier
(Autosamdri 814; Tousimis Inc., Rockville,
MD, USA), sputter-coated with 10 nm gold,
and viewed with a JEOL JSM6400 scanning
electron microscope (JEOL USA, Peabody,
MA, USA) operating at 10 kV. 
BT products and subfractions. We used
primarily the BT products F48B (Btk strain
HD1) and VB12AS (Bti strain HD14);
however, several others were also investigated
and are described in detail elsewhere, along
with methods of manipulation and quality
control analyses (2,5,7). The concentration of
any BT product or derivative subfraction (also
vegetative cells) was determined according to
recently validated methods (7,13) and
expressed as percent of BT product or equiva-
lent, based on the content of viable spores or
bacterial cell and/or protein contents relative
to contents of undiluted (whole) BT product
as the standard. Generally, side-by-side com-
parisons of BT products required only minor
volume adjustments (< 5%) to equalize spore
contents. BT subfractions were prepared by
carefully partitioning each BT product into
supernatant (particulate-free) and pellet (par-
ticulate-rich) fractions by centrifugation
(12,000 ×  g for 10 min at RT). Particulate-
free filtrates (PFF) were made by filtering
(0.45 µm pore size) the supernatants diluted
to 10% (v/v) with phosphate-buffered saline
(PBS). Alternatively, PFFs were ﬁrst concen-
trated 20-fold by reverse osmosis for 6 hr at
4°C. Semipurification of the PIB fractions
was performed according to Thomas and
Ellar (10) with the following modiﬁcations:
500 µL aliquots of each BT product were
diluted 2-fold and vigorously vortexed (5
min at RT) with 50 µL sterile crushed glass
to disrupt aggregates. After the discontinuous
sucrose gradient centrifugation step (80,000
×  g for 14 hr at 4°C, using a Beckman
SW50.1; Beckman Instruments, Mississauga,
Ontario, Canada), the crystal-rich PIB layer
was verified by SEM and protein analysis.
Sucrose was removed by dilution with two
volumes of ice-cold double distilled H2O and
centrifugation. This purification procedure
was repeated 3 times. Solubilization of PIB
contents and conversion of pro-δ -endotoxin
(~ 132–137 kDa) to activated δ -endotoxin
(~ 60–67kDa) involved incubating either BT
products or PIB-enriched fractions in 40
mM sodium carbonate (pH 10) and trypsin
(0.1% w/v) at 37°C (10). We used protein
electrophoresis to monitor digestion, and we
collected residual particulates, including all
spores, by centrifugation followed by mem-
brane filtration (0.2 µm pore size). Equiv-
alent dose was based on spore count and total
protein of BT product. 
Preparation of vegetative cell cultures and
exoproteins. Spore outgrowth from BT prod-
ucts as well as from the controls, B. cereus
(ATCC 14579; lot 90-07SV), B. subtilis
(ATCC 6051; lot 91-11SV), and E. coli
C600 (ATCC), were grown in Luria-Bertani
(LB) broth at 37°C for 6–18 hr. Alternatively,
they were grown in Grace’s insect cell medi-
um or DMEM with or without human cells.
Following enumeration of colony-forming
units (cfu) per milliliter (2), each culture was
adjusted to a concentration equivalent to
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with PBS. Cultures were partitioned into cell
(pellet) and cell-free (supernatant) fractions by
centrifugation (12,000 ×  g for 10 min at RT).
The supernatants, or VCPs, were ﬁlter steril-
ized (0.22 µm pore) before and after concen-
trating 1,000-fold by reverse osmosis (6 hr at
4°C). We monitored VCP production from
washed cells after cells were rapidly resuspend-
ed in the same volume of fresh culture medi-
um and harvested at various times thereafter.
We conducted various stability tests on VCP
before it was tested with human cells. 
We inclubated aliquots of VCP (1 mL) at
0–100°C for intervals from 10 sec to 48 hr.
Samples were also subjected to freeze–thaw
from –80°C to 37°C in 15 min cycles and
treatment with proteases (trypsin at 0.25%
w/v or proteinase K at 0.0001% w/v) for vari-
ous time intervals at 37°C. For control sam-
ples we used Grace’s insect cell medium or
DMEM treated in the same manner as the
VCP. We used a series of molecular mass cut-
off membranes (Centricon 10–100 kDa;
Amicon, Beverly, MA, USA) and gel ﬁltration
(Sephadex G-150,100,50; Amersham
Pharmacia Biotech, Baie d’Urfè, Quebec,
Canada) to approximate the dynamic size and
homogeneity of the VCP toxic constituent(s). 
Bioindicator assays. Bioreduction or cell
redox activity, measured by MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazoli-
um bromide; Sigma Chemical Co., St.
Louis, MO, USA) and polypeptide analyses
and immunodetection assays were conduct-
ed as described for insect cells (4,7).
Electrophoretically separated polypeptides
were stained with either 0.1% Coomassie
Blue or silver nitrate. We obtained anti-actin
(5 µg/mL), anti-cyclin (5 µg/mL), and anti-
tubulin (2 µg/mL) antibodies from Roche
Diagnostics (Laval, Quebec, Canada). Other
probes included anti-cry 1Ab and 1Ac anti-
bodies (1:500 dilution; Agdia Inc., Elkhart,
IN, USA), anti-glutathione-S-transferase
(1:20 dilution; Cedarlane, Hornby, Ontario,
Canada), and anti-heat shock proteins 60
(hsp60; 10 µg/mL; Monosan, Am Uden,
Netherlands) and 70 (hsp70; 11 µg/mL;
Sigma). Specificity was based on the
polypeptide target size (diagnostic molecular
mass) and the absence of cross-reaction with
polypeptides from either BT products or
vegetative B. thuringiensis cultures. In radio-
labeling experiments, we incubated HT29
monolayers with 35S-methionine (8.5 µCi/L
DMEM, methionine free) in 30 min pulses
before or during the dosing regime. At each
end point, the supernatants containing any
detached cells and cellular debris were
transferred to microtubes and frozen at
–80°C or centrifuged (1,000 × g for 10
min) first to recover fully intact cells.
Radiolabeled polypeptides were assessed by
autoradiography (Kodak X-Omat XAR-5;
Sigma) after gels were dried and sprayed
with radiosensitive ﬂuor (EnHance; Dupont,
Mississagua, Ontario, Canada). For quantiﬁ-
cation, X-ray ﬁlms were exposed for varying
durations at –80°C to achieve optimal band
resolution before densitometry (7). 
Results
Cytotoxic effects of whole BT products. In
preliminary studies, several human cell lines,
as well as those derived from monkey,
mouse, and sheep, were exposed to an array
of dilutions of whole BT products or deriva-
tive fractions. The results from all of these
assays, albeit extensive in detail, were
nonetheless nearly identical, including those
that compared the apical and basal surfaces of
cell monolayers with semipermeable mem-
branes which can separate human cells from
actual contact with bacteria and PIB struc-
tures of BT products or derivatives. The key
difference that distinguished between assaying
cells in suspension culture and assaying cells
conﬁgured as monolayers was the degree of
difficulty in collecting data. The former
necessitated additional steps to physically sep-
arate BT-related components from both
undamaged and damaged cells and to moni-
tor intermediate changes by microscopic
methods. For these reasons, we chose to illus-
trate most of the salient data with experiments
using one human cell monolayer system. 
As illustrated in Figure 1A with HT29
cells, quantiﬁcation of bioreduction activity
showed only marginal decreases (< 10%) as
long as antibiotic was present, even when
exposures were extended up to 24 hr.
However, without antibiotic, the loss in
bioreduction activity was essentially 100%
with all doses > 5 × 10–14% BT product/tar-
get cell. In the dose range of 10–14 to
5 × 10–14% BT product/target cell, a thresh-
old response was seen with both Bti and Btk
BT products. This threshold dose (Dt)
response was generated by the presence of one
spore per assay. Experiments involving short
exposure intervals indicated that the earliest
bioreduction changes began between 2 hr to 4
hr at doses ≥ 10–7% BT product/target cell or
~1 0 7 Dt. The results from several dose–time
assays, conducted in experiments shown in
Figure 1A, were used to derive dose–response
times that correspond to target cell LD50,
referred to here as tLD50. Using this method,
Bti and Btk BT products generated virtually
identical tLD50 values. The dose–response
data (n = 30 separate experiments) using ﬁve
different human cell systems are summarized
in Figure 1B. The timing differences between
suspension and monolayer-propagated cell
types can be accounted for by the additional
steps in the assay procedure required for cells
in suspension. 
Studies on the changes of human cell
morphology and bioreduction loss conducted
over various exposure regimes established
that loss of bioreduction corresponded direct-
ly with numbers of human cells exhibiting
visible damage. For example, exposures of
10–7% BT product/target cell (Figure 2A)
resulted in a 50% loss in attached cells by 4.4
± 0.3 hr and a corresponding loss in biore-
duction capacity at 4.4 ± 0.4 hr (Figure 1B).
Enumeration of the shed cells based on
separate exposure assays (n = 20) revealed
that 43 ± 12% of the cells had degraded
beyond recognition as long as one spore was
present per assay well and its outgrowth was
permitted. Companion studies using SEM
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Figure 1. Changes in human cell bioreduction activity after exposure to commercial BT products. (A) Time
course of HT29 cell exposure to various concentrations of BT product per target cell. Bioreduction was
assayed as described in “Materials and Methods.” The dashed line indicates a 50% loss of the cell popu-
lation’s bioreduction activity. Data for 10–11, 10–10, and 10–8% BT product doses are not shown. Data points
for Bti and Btk -BT products completely overlapped and are the means of at least three separate determi-
nations ± SD. In the presence of antibiotic (gentamicin), all BT doses gave results equivalent to 10–14% BT
product/target cell. (B) Average dose response (tLD50) values computed from 120 exposures of Bti and
Btk BT products using various human cell types propagated as monolayers or suspension cultures (see
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10–9 % BT 10–7 % BT 10–6 % BTconfirmed the dramatic changes between
control (Figure 2B, C) and treated cells
(Figure 2D, E). In addition to numerous veg-
etative cells adhering to the surfaces of the
residual HT29 cells, the microvilli of these
cells were absent and none of the cells were
actually intact (Figure 2E). 
Further investigations were made to
establish the fate of cellular proteins by
immunodetection. Because the results from
the six proteins were very similar, examples
of actin and cyclin (an exception) are shown
to demonstrate derivation of half-lives of
these proteins. As shown in Figure 3A–D
using data from 10-7% BT product/target
cell, the variation in half-life of cellular pro-
teins was 4.7–5.5 hr. They correspond to the
tLD50 values derived from enumerating
attached cells. The early drop in HT29
cyclin content may be unique, as other cell
systems exhibited little or no expression of
this isoform. Similar analysis of the shed cell
fraction indicated that concentrations of all
of the protein markers (including total pro-
tein) were underrepresented by at least 80%.
This pattern of degradation of cellular pro-
tein was virtually identical to that seen in
exposure regimes using the Bti-based com-
mercial product. 
BT product particulate-free fractions.
We assessed the cytotoxic contribution of
the liquid PFF of BT products before and
after micropore ﬁltration (Figure 4). These
fractions were free of spores and aggregates
of any kind, as observed by phase-contrast
microscopy, SEM, and incubation on LB
agar plates. The polypeptide contents of BT
products and PFFs (concentrated 10 times)
are shown in Figure 4A. The most abundant
polypeptides in Btk BT products were those
corresponding to pro-δ -endotoxin (132–134
kDa) and activated-δ -endotoxin (60–67
kDa) pools. In the case of the Bti product,
there was an additional polypeptide with a
molecular mass of the CytA toxin (24–27
kDa) (10). 
The PFF was ~ 67% of whole Bti or Btk
BT product volume, but it contained
≤ 0.02% total BT protein (or 5 µg/mL). The
Btk polypeptides measured 18, 34, 80, and
> 200 kDa, whereas those of Bti PFF
measured 34 and 95 kDa. When either of
these PFF sources was used in exposure assays,
the bioreduction activity of human cells
decreased, but as shown in Figure 4B, this
occurred only with doses equivalent to
≥ 10–4% BT product/target cell. This dose is
~ 1,000-fold over the BT product dose rou-
tinely used in other experiments (Figures 2
and 3). Comparisons of phase-contrast micro-
graphs of HT29 cells exposed to PBS or Btk
PFF (Figure 4C, D) revealed that treated cells
remained attached during the 24-hr exposures
and that they had lost tight cell-to-cell associ-
ations (junctions) compared to PBS-treated
cells. Occasionally treated cells formed
cell–cell fusions or syncytia (Figure 4F). In
treatments with Bti PFF, entire monolayers
detached within a 2-hr exposure interval
(Figure 4G). However, these cells still exhibit-
ed tight junctions and redox activities (Figure
4H) comparable to PBS-treated cells (Figure
4E). Also, these cells could be replated and
grown with a viability > 95%, essentially
comparable to that seen with trypsin (2.5
mg/mL) treatment, routinely used in the pas-
sage of cell monolayers.
Cytotoxic effects of parasporal inclusion
bodies. We used discontinuous sucrose gradi-
ent centrifugation to enrich for PIB struc-
tures of BT products. The fractionation of
Articles • Tayabali and Seligy









































Figure 2. Changes in HT29 cell number and morphology during exposure to BT products. (A) The time course shows the number of attached and shed cells during
exposure to PBS or 10–7% BT product/target cell. The half-life (tLD50), based on time required for 50% loss of the attached cells was 4.4 ± 0.3 hr. The dotted line
represents the expected number of shed cells based on controls and remaining attached cells at each time point. (B–E) Scanning electron micrographs of HT29
cells exposed for 6 hr to either PBS (B, C) or BT product (D, E).Btk products routinely gave five opaque
particulate layers (bands), whereas the Bti
product resulted in only four. Polypeptide
analysis of these fractions indicated that the
bulk of Btk δ -endotoxin proteins (67kDa
and 132 kDa) were found in fractions 3 and
4 (Figure 5A, fractions 3 and 4). However,
SEM analysis revealed that fraction 4 con-
tained the most PIBs (Figure 5B), represent-
ing a 9-fold increase over the original spore
content. In addition, cuboidal crystals were
frequently seen (about one per every four
Btk spores). For Bti, fraction 3 had the high-
est content of polypeptide and spherelike
PIBs (relative to spore number)(Figure 5C,
fraction 3, and 5D). Solubilization of the
PIB enrichments was accomplished by treat-
ment with buffer, pH 10, and trypsin.
Solubilized Btk fraction 4 (centrifuged and
filtered) contained only the 63–67 kDa
polypeptides (Figure 5A, lane 7), whereas, in
addition to the 67 kDa polypeptide, the
spore-rich pellet also contained spore-related
products ~ 5–30 kDa and >200 kDa in size.
The ﬁltered supernatant of solubilized Bti frac-
tion 3 (Figure 5C, lane 6) had both 22 and 27
kDa polypeptides, and the corresponding
spore-rich pellet (lane 7) had the 78 kDa
polypeptide but no 22 kDa constituent. 
As shown in Figure 6A, results were dif-
ferent when fractions enriched in intact PIBs
and solubilized versions were exposed for 4
hr. Intact PIBs from either Bti or Btk sources
registered little effect. However, the use of sol-
ubilized Btk PIB gave a linear response and, at
doses of 100 µg/mL, resulted in 30% loss of
bioreduction activity. This dose is about 100
times greater than the highest dose of BT
product routinely tested. Identical assays with
solubilized Bti PIB initially followed the Btk
proﬁle, but then rapidly changed as its dose
was increased (Figure 6A). These levels of
cytotoxicity changed little (~ 5%) on retesting
at 6 hr. In controls, HT29 cells were treated
separately with carbonate buffer and trypsin.
All of these treatments resulted in ≤ 10% loss
in bioreduction. 
We conducted experiments involving the
measurement of cell proteins. Results with
intact PIB treatments were the same as
untreated controls. As shown in Figure 6B,
actin levels and attached cells only gradually
decreased as the dose of solubilized Btk-PIB
or Bti-PIB was increased up to 100 µg/mL.
The loss of these two indicators was 30 ± 10
%. However, the corresponding SEM analysis
revealed no obvious change in either mor-
phology or volume of attached cells, and shed
cells also appeared to be intact (35). Assuming
a linear dose response, extrapolation of the
curves in Figure 6B would predict an LD50 of
130–140 µg/mL.
Experiments with a commercially avail-
able antibody probe considered speciﬁc for
cry1Ab and 1Ac δ -endotoxins (see “Materials
and Methods”) indicated that cultures of Btk
spores produced detectable amounts of these
Articles • Human cell toxic effects from Bacillus thuringiensis insecticides

















































Figure 3. Changes in speciﬁc proteins during HT29
exposure to BT products. Example immunoblot
assays for actin (A) and cyclin (B) after exposure
to 10–7% BT product/target cell (see “Materials
and Methods”). Lane 6S shows only trace levels
of actin and cyclin in shed cells at 6hr. (C and D)
Predicted tLD50 values determined from the quan-
tification of proteins of attached cells.
Abbreviations: ACT, actin; GST, glutathione-S-
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Figure 4. Protein content and toxicity of BT product particulate-free supernatant fractions. (A) Coomassie-
stained SDS-PAGE gels of undiluted Btk and Bti BT products (4% ﬁnal) and corresponding (PFFs concen-
trated to 10X (10 µL/lane). (B) Bioreduction assay of HT29 cells exposed 24 hr to PBS or a series of PFF
dilutions. Antibiotic had no effect. The dashed line represents the artifactual loss of bioreduction due to
premature shedding of the entire monolayer induced by Bti PFF trypsin-like activity. Data are from three
determinations ± SD. (C–H) Phase-contrast micrographs of HT29 cells exposed 24 hr to PBS (C,D,E) or
PFFs of Btk (D,E,F) or Bti (F,G,H) products at a dose equivalent to 10–4% BT product/target cell.
Comparison of 1× (D,G) and 15× (E,H) image magniﬁcations of monolayers in assay wells directly after
MTT-formazan production shows the release of the entire monolayer (or portions of it). polypeptides, but only at about 18 hr and up
to at least 48 hr of culture (35). This expres-
sion proﬁle corresponded favorably with the
initial buildup of spores, but not with the
cytotoxic activity produced by exposing
human cells to BT product for only 4–8 hr in
the absence of antibiotic. These data added to
the certainty that the cytotoxicity observed
from BT products was not attributable to
either PIBs present within BT products or
“second generation” PIBs generated from
sporulated cultures.
Cytotoxicity of vegetative cells and their
exoproducts. Exposures to intact or solubilized
PIBs and the liquid, particulate-free fractions
of BT products (Figures 4 and 6) caused little
human cell damage as compared to that seen
whenever spores were present and their out-
growth was not prevented by antibiotic.
Further investigations revealed that there was
a dependence on the presence of human cells
for efﬁcient vegetative cell and VCP produc-
tion to occur from spores. Also, peak destruc-
tion of human cells occurred early during the
buildup of vegetative cells, and this cytotoxic-
ity (per microgram of total VCP) produced
by either Btk or Bti cells exhibited a relative
decrease as these cells entered sporulation
phase and other proteins accumulated after
approximately 18 hr. Experiments with a
commercially available antibody probe 
considered specific for cry1Ab and 1Ac δ -
endotoxins (see “Materials and Methods”)
indicated that cultures of Btk spores pro-
duced detectable amounts of these polypep-
tides but only at about 18 hr and up to at
least 48 hr of culture (35). This expression
proﬁle corresponded favorably with the ini-
tial buildup of spores (also seen for Bti), but
not with the cytotoxic activity produced by
exposing human cells to BT product for only
4–8 hr in the absence of antibiotic. These
data add to the certainty that the cytotoxici-
ty observed from BT products was not
attributable to either PIBs present within BT
products or “second generation” PIBs gener-
ated from sporulated cultures.
In the absence of human cells, spore out-
growth was found to be ≤ 4% in either fresh
DMEM or in medium conditioned for 8 or
24 hr with any of the human cell monolay-
ers. These observations are in contrast to
those using Graces’ insect cell medium,
which alone supports spore outgrowth at lev-
els comparable to or better than in LB broth
(2). However, in all types of media, where at
least some spore outgrowth actually occurred,
the VCP cytotoxicity levels were comparable
if they were made relative to number of vege-
tative cells. To simplify our investigations, 8-
hr outgrowths were mass-produced from BT
products incubated in Graces’ insect cell
medium without FBS. The removal of FBS
eliminates its masking of cell proteins during
analysis. Tests showed that the absence of
FBS shifted the Bti/Btk growth curves by ~ 2
hr, but otherwise had little or no effect on
the level of VCP exocytolytic activity pro-
duced by either Btk or Bti sources. In addi-
tion, we removed fine particulate matter
(spores, vegetative cells, cell wall debris, and
potentially PIB) from culture supernatants by
filter sterilization before concentrating and
retesting supernatants. These steps also had
little effect (< 5%) on the severity of the
cytolytic response, but improved the storage
qualities of VCP stockpiled at various stages
of cultures harvest from 4 hr to 48 hr. 
In 2-hr exposure regimes with Btk VCP
from 8-hr cultures, we observed considerable
cell damage as compared to control cells
(Figure 7), but the overall damage was no
different than that seen in exposures with BT
product (Figure 2). In assays using VCP dilu-
tions, there was a saturation effect at 0.5X to
1X VCP, as both doses generated similar
tLD50 values of 6–8 min (Figure 7E). Based
on the number of vegetative cells present at 8
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Figure 5. Properties of PIB enrichments and their solubilized derivatives. SDS-PAGE analysis of PIB enrich-
ments obtained by sucrose gradient centrifugation using (A) Btk and resultant fractions (lanes F1–F5) and
(C) Bti BT products and resultant fractions (lanes F1–F4). Fractions were trypsin solubilized (SOL) and sepa-
rated into supernatant ﬁltrate (FILT) and a spore-containing pellet (PEL). (B) SEM of Btk fraction 4 [shown in
(A)], the most enriched for Btk bipyramidal PIB crystallike structures. (D) SEM of Bti fraction 3 BT product
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Figure 6. Cytotoxicity of PIBs and solubilized derivatives. (A) Changes in HT29 cell bioreduction activity after
exposures to dilutions of unsolubilized fractions (F) and their trypsin-solubilized (SOL) ﬁltrates. In all cases,
the exposures were for 4 hr at 37°C with antibiotic added as a precaution to control possible spore contami-
nation. (B) Corresponding changes in cell number and actin levels of attached HT29 cells after exposure to
trypsin-solubilized PIB of Btk or Bti. All data points are the means of four separate experiments ± SD.hr, 0.5X VCP was estimated to be equivalent
to approximately 1.4 × 10–7% BT product
(spores)/target cell. In parallel assays with
0.5X VCP, the average tLD50 value predicted
by loss of speciﬁc proteins and cell adhesion
was 42 min for hsp 60 and hsp 73, 60 min
for actin, and 90 min for loss of cell adhesion
(Figure 7F). Corresponding analysis of the
shed cell population indicated total cytolysis
and an inconsistent loss of protein indicators
(Figure 7F). In all of these assays, Bti VCP
gave results similar to those of Btk VCP, if
based on an equivalent number of Btk vege-
tative cells or the total Btk protein content. 
Further exposure tests using washed vege-
tative cells determined that an LD50 required
at least 1.5 hr of preincubation or at least one
vegetative cell doubling to take effect. The
addition of gentamicin also decreased the
regenerated cytolytic activity by > 90%. Also,
based on total protein content per bacterial
cell, VCP cytolytic activity harvested at later
stages of culture decreased rapidly (> 90% by
18–20 hr). These results show that the pro-
duction of cytolytic factor(s) is likely depen-
dent on the early growth phase and de novo
synthesis rather than on the simple release of
presynthesized product(s). 
VCP effects on human cell protein
biosynthesis. We investigated possible effects
of VCP on human cell protein synthesis by
examining changes in the polypeptide com-
position of each human cell type used in
time-course experiments of 0–24 hr expo-
sure. These experiments involved protein
staining (silver or Coomassie blue) and
demonstrated that loss was not specific to
any protein species (35). To detail early
events, HT29 cells were pulsed with
35S-methionine at 30 min intervals over a
6-hr exposure period, using either PBS or 8-
hr VCP at a dose equivalent to 1.4 × 10–7%
BT product/target cell. Resultant autoradi-
ographs of 35S-labeled polypeptides (Figure
8B, C) permitted calibration of the changes
in protein synthesis of attached cells. In con-
trol experiments, we detected > 150 putative
polypeptide products using various autoradi-
ographic exposures. With VCP treatment,
polypeptide synthesis was rapidly reduced
without apparent bias for any abundant
polypeptide species. The corresponding
tLD50 estimate for loss of 35S-methionine
incorporation was ≤ 15 min or approximate-
ly one-fourth to one-third the rate of loss of
speciﬁc protein indicators (see “Cytotoxicity
of vegetative cells and their exoproducts”).
At the same time, the 35S label associated
with cell shedding (Figure 8C) was < 7%
that of control cells and soon reduced to
background levels thereafter. This indicates a
rapid shutdown of protein synthesis culmi-
nating in a less rapid, nonspeciﬁc degrada-
tion of various cellular proteins.
VCP properties. Polypeptide analysis of
VCP produced at various stages of spore out-
growth indicated considerable size hetero-
geneity, ranging from 5 kDa to > 200 kDa.
Tests conducted before and after crude frac-
tionation of the nondenatured VCP, using
selective membrane (pore size) filtration as
well as gel and bead matricies (see “Materials
and Methods”), indicated that the cytolytic
constituent(s) was between 50 and 100 kDa
in size. In terms of total protein, this activity
was approximately 20 times higher in VCP
harvested at 6–8 hr than at 18–24 hr when
spores and cry products accumulate (see “VCP
effects on human cell protein biosynthesis”)
(34). Neither Btk nor Bti VCP activity was
affected by repeated freeze–thaw cycles (ﬁve
10-min cycles of –80°C to 3°C) and storage
up to 3 years at –80°C or –20°C. However,
the half-life of VCP activity decreased from
40 hr to 24 hr when samples were pretreated
at 23°C and 50°C, respectively, and to ≤ 5
min at 60°C. This inactivation was nonre-
versible and was similar to a pretreatment
with a broad-spectrum protease (100 µg/mL
proteinase K) for < 2 hr at 37°C. However,
VCP activity was not affected by trypsin
(0.025–0.25%, w/v), serine protease inhib-
itors, a chelating agent (0.1–10 mM EDTA),
and agents such as cholesterol (60 µg/mL),
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Figure 7. Cytotoxicity of VCP. HT29 cells were exposed 60 min to either PBS (A,C) or VCP (B,D) derived from
a 6-hr outgrowth of Btk BT product (see “Materials and Methods”). The VCP concentration (1.0X) was
equivalent to the output of one vegetative cell/target cell or approximately 3.5 × 10–7% BT product/target
cell. (E) Changes in bioreduction activity during the time-course exposure to PBS or VCP diluted to 0.1X,
0.25X, 0.5X, or 1.0X of the stock dose. These data were adjusted (subtracted) to take into account contribu-
tions from Bt-related exoreductase activity that otherwise would give an underestimation of toxic effects.
The arrow shows characteristic initial overstimulation effect. (F) Changes in attached cell number and cor-
responding levels of actin and hsp73 after exposure to 0.5X VCP. The dashed line indicates the proﬁle of
detached cells. The inset shows a sample immunoblot using total protein from lysates of attached cells
separated by SDS-PAGE and probed with the actin antibody.nicotinamide adenine dinucleotide (NAD;
≤ 0.1 mM), and adenosine triphosphate
(≤ 0.1 mM), which are suggested to inhibit or
modify activities of B. cereus (18). In all cases,
control tests with these agents (no VCP)
resulted in losses of bioreduction of ≤ 5%.
Exposures to VCPs from other bacterial
species. Stocks of B. cereus, B. subtilis, and E.
coli cells and their VCPs were prepared in the
same manner as those derived from Btk and
Bti spore outgrowths. The tests with B. cereus
(spores or vegetative cells) showed that both
biomass and VCP cytotoxic effects were
comparable to those of Bti and Btk cells
(Figure 9A–C). In contrast, B. subtilis and E.
coli produced only approximately 1% of the
B. thuringiensis biomass (Figure 9A). The
strong binding to human cells exhibited by
B. subtilis and E. coli inﬂuences human cell
MTT substrate utilization by either increas-
ing or decreasing bioreduction activity in
relation to untreated control cells (Figure
9B). In all cases, these negative changes could
be blocked by gentamicin to arrest vegetative
cell activity. After pooling and concentrating
the VCPs from several experiments, we
found that levels of some target cell bioindi-
cators were greatly reduced, but only in the
case of B. cereus VCP (Figure 9B, C). 
Discussion 
Complexity of biopesticides and dose estima-
tions. As compared to chemical pesticides,
the details provided in material safety data
sheets for biopesticides are unusually sparse
and vague, considering the extent to which
they are used and promoted for community
and even household use. Recently we
addressed some of these data gaps (2–5,7) by
introducing sampling strategies and physical,
biochemical, immunologic, and molecular
genetic methods that should be applicable
for assessing quality control and quantiﬁca-
tion of health effects and efficacy of these
and other biotechnology products, including
transgenic plant derivatives, intended for
release into the environment. The data
derived from the analysis of several BT prod-
ucts demonstrate that these products are
inherently heterogeneous and impure with
respect to a deﬁned active ingredient when
compared to chemical counterparts. 
The most common descriptors used by
the industry for Btk- and Bti-based products
in parallel calibrations are the international
unit (IU) and the percentage of “active ingre-
dient”. The IU is essentially an arbitrary unit,
reﬂecting a relative measure of insect larval
death attributed to ingestion of BT product
(1,36–38). In terms of abundance, the two
most consistent and dominant components
of BT products that we have found are the
spores, which in most cases actually exceed
1013/L, and the PIB crystalloids, whose con-
centrations are equal to or often 25%–50%
of the spore content (5,36). In the promotion
of BT products, the “active ingredient” has
been considered synonymous with δ -endo-
toxins, encoded by various cry genes, whose
presence or absence in plasmid form justiﬁes
the rationale for subspecies classiﬁcation (6).
However, the assumption that the sole toxic
ingredient is equivalent to that reported from
using laboratory-processed and purified 
δ -endotoxins merits debate because in most
cases the importance of controlling spore
contamination and related effects was not
recognized. 
Given the complexity of current BT
products, it is difficult to rationalize what
either the IU or percent of “active ingredient”
directly measures in the context of environ-
mental applications (36–38). Our previous in
vitro toxicology tests with insect cells showed
that spores played a major role as a toxic
ingredient, requiring about the same time
interval for septicaemia to take place as for
effects predicted from the in vivo breakdown
of PIBs (4,7). In those experiments, the dose
was expressed in terms of IU per target cell,
where it was determined that 1 IU was equiv-
alent to approximately 2,400 spores (2). For
the baseline study of human cell effects pre-
sented here, all the data were expressed as
percent of BT product per target cell. This
format allows us to assess (or reassess at a later
date) any subcomponent of these BT prod-
ucts as long as the concentration is known in
relation to other known components (e.g.,
spores). This approach would also be useful
for testing plant biotechnology products as
fresh or dried powders. Further, by supplying
appropriate parameters about the target cell or
tissue/organoid assay system (e.g., number
and types of cells in suspension per milliliter
of culture medium or per square centimeter
of surface), any manner of exposure unit can
be derived. For our purposes, because of the
abundance, hardiness, and likelihood of
potential risk (13,37), we used the spore to
estimate relative enrichment and dose equiva-
lence of PIBs and also vegetative cells and
their exoproducts. Thus, a typical aerial appli-
cation potentially delivering approximately 3
× 1010 IU/hectare or approximately 300
IU/cm2 (~ 7.2 × 105 spores/cm2) (2,13,37)
would equate to a dose of approximately 2.4
× 10–5% BT product/cm2 or 10–10% BT
product/target cell as tested in this study.
Also, in relation to target insects, such a dose
would be intermediate to those contained
within the 52–84 µm diameter BT droplets
that gave maximum (optimal) larval mortality
over a 1-week exposure interval (38). From
this dose optimization and an approximation
of the surface area of an insect larval midgut
(< 0.013 cm2), the in vivo cell surface dose
would be ≥ 1.5 × 10–12% BT product/target
cell, which falls within the range for human
cell assays. 
Toxicity of BT products and subcompo-
nents in the absence and presence of antibiotic.
In the absence of antibiotic, all doses from
approximately 5 × 10–14% to 10–5% BT
product/target cell were cytotoxic to all types
of human cells tested. Detailed tests with
serial dilutions of BT products indicated that
the threshold dose would be approximately 5
× 10–14% BT product/target cell. At this
dose, the tLD50 was approximately 16 hr, a
time point corresponding to when a single
spore (per assay well) has reached midexpo-
nential growth. Similarly, differences in
spore contents of the various subfractions
tested were found to account for the
observed differences in lag time before dose-
induced cell changes were observed. Thus,
the no-observed-adverse-effect level
(NOAEL) of BT products and their subfrac-
tions would correspond to doses in which
there were either no spores present or there
was an inhibitor (antibiotic) present to block
spore-associated activity. In the latter case,
concerning whole BT products and their
particulate-rich (pellet) and particulate-free
(supernatant) fractions, the dose deﬁning Dt
or the NOAEL was shifted upward by a
factor of ≥ 109, which indicates that the
most damage-causing agent(s) arises from
viable spores within BT products. These
results cannot be explained by contamina-
tion of these BT products with unrelated
organisms (5,7). 
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Figure 8. Effects of VCP exposure on 35S-methion-
ine-labeling of HT29 polypeptides. (A) Assays
involved incubation with 35S-methionine for 30-min
intervals (indicated by shaded bars) before and dur-
ing exposure to Btk VCP stock made equivalent by
dilution to 3.5 × 10–7% BT product/target cell. Total
protein synthesized by cells that were attached (B)
and shed (C) during VCP exposure was analysed by
SDS-PAGE. Distribution of 35S-label was detected
by autoradiography (see “Materials and Methods”). The differential response between low
and high doses of BT products (see summary
Figure 1B) or of subcomponents with equiv-
alent amounts of spores provides clues as to
the mechanism of toxiﬁcation at work. With
low concentrations of spores, the lag time in
toxic response per dose was similar to the
regular shift (~ 40 min) in occurrence of
early-to-middle vegetative cell production
for each log10 dilution step of Btk or Bti BT
product at 37°C (2). This indicates that at
low doses (< 10–12% BT product/target cell)
the inherent number of spores, on conver-
sion to vegetative cells, must produce several
generations of cells in order to build up the
critical amounts of toxic ingredient(s) neces-
sary to kill ≥ 50% of the target cells present.
However, with BT product doses in or
above the optimized range used for aerial
spray applications, the response times were
essentially clustered (tLD50 = 3.9–4.8 hr),
indicating that the number of spores is
already near or may exceed the number of
vegetative cells needed (on conversion) to
generate sufﬁcient cytotoxic product(s). Our
rough estimates indicate that the minimum
number of vegetative cells required to pro-
duce a cellular LD50 would be ≤ 10% of the
target cell concentration or approximately
105 vegetative cells/mL of nutrient medium.
In a nonmammalian environment, tempera-
tures below the optimum growth range of
34–37°C would retard the rate of vegetative
cell ampliﬁcation (septicaemia) and buildup
of lytic damage, thus signiﬁcantly delaying
uniformity of toxic response and death in
insect target organisms (2,7,13,38). 
Toxicity of activated δ -endotoxin(s). The
supernatant fraction (with antibiotic) and its
ﬁltered version were shown to be essentially
nontoxic unless used at near full BT product
strength. Aside from its coloration (usually
brownish yellow), the supernatant (1X) frac-
tion of either Bti or Btk BT product sources
contained < 0.02% of the total protein con-
tent and only a few discernable polypeptides,
which did not resemble constituents detected
in PIB enrichments. Further, the Btk fraction
failed to react with commercially prepared
cry1Ab or 1Ac antibody probes (35), indicat-
ing that little or no “activated” δ -endotoxin
material may be present. After the BT prod-
uct was concentrated to an equivalent Dt of
≥ 1010, the Btk and Bti supernatants caused
multicell fusions and shedding, similar to
that seen after treatment with a virus or poly-
ethylene glycol (35,40). This shedding may
be caused by trypsin-like protease activity,
and the presence of such factors in BT prod-
ucts suggests a carryover of fermentation
products as noted for β -lactamase (5,13).
Because of their actual concentration in spray
droplets, these fermentation residues may
play a role in the variation of product efﬁcacy
and potential health effects (3,13). 
Aside from the liquid and spore fractions,
the only other major constituent of BT prod-
ucts is the rather heterogeneous collection of
protease-sensitive amorphous and crystallike
PIB particulates. The PIB structures are usu-
ally less abundant than spores (2,5), but in
theory should be equal in amount (1,36).
SEM and light microscope analyses with pro-
tein stains indicated that both types of partic-
ulates have protein as a major part of their
composition. Because similar amorphic struc-
tures were also seen in Btk and Bti vegetative
cell phase cultures (35), we suggest that the
amorphic particulates are aggregates of
exopolypeptides and possibly other culture
residues. After treatment with a broad-sub-
strate protease and detergent, > 90% of the
spores in BT products can be recovered free
of protein, mainly those related to the pro-δ -
endotoxins and their cleavage products (2).
However, in our experience using BT prod-
ucts and various puriﬁcation methods for δ -
endotoxins (10,39,41–46), deﬁnitive, quanti-
tative separation of amorphous and crystal-
like PIB particulates from each other, and
from spores and other cellular debris, is not
very realistic. When tested at concentrations
up to 100 µg/mL (~ 1.6 × 10–5% BT prod-
uct/target cell), exposures using either Bti or
Btk PIB enrichments estimated to be 9-fold
relative to spore content showed only tran-
sient changes (Figure 6) as long as antibiotic
was present to control spore contamination
(35). There were no distinct changes in cell
morphology, and cell viability was ≥ 95%
with subsequent changes of medium and cell
passage. The lack of cytolysis with Bti PIB,
which contains CytA protein (~ 10% of the
total protein), indicates that it may be
unavailable to interact with target cells as
reported earlier (8). 
Following PIB solubilization with
trypsin treatment, we found that residual
aggregates and spores could be effectively
removed by microﬁltration, as shown by the
absence of bacterial colonies after culturing
ﬁltrates for 48 hr. With the Btk BT product,
this approach resulted in the disappearance
of 200 kDa and 132–134 kDa proteins and
a marked increase in 63–67 kDa product
(Figure 5A), consistent with a conversion of
pro-δ -endotoxin to “activated” δ -endotoxin
(1,6,10). The trypsin treatment of Bti BT
product resulted in a similar pattern of
polypeptide solubilization; its unique
polypeptide proﬁle may account for the dif-
ferences in bioreduction response, which was
not seen when either cell or actin content
was assayed (Figure 6A, B). The dose-depen-
dent changes using these two bioindicators
for Bti and all three bioindicators for Btk
indicate a crude linear response beginning at
a dose of approximately 5µg/mL (~ 10–6%
BT product/target cell) with an extrapolated
tLD50 of approximately 130–140 µg/mL.
This dose corresponds to approximately 2 ×
10–5% BT product/target cell or ≥ 4 × 108
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Figure 9. Toxic effects of B. subtilis, E. coli, and B. cereus and their VCPs. (A) Growth of B. cereus (Bc), B. subtilis (Bs), E. coli (Ec), and B. thuringiensis (Btk or Bti)
incubated at 37°C in DMEM without phenol red and antibiotic and in the presence (+) or absence (-) of HT29 cells. Changes in optical density (OD; 450nm) caused
by vegetative cell production (biomass) were automatically recorded every 15 min. (B) Changes in HT29 bioreduction activity after 24 hr exposure to Bc, Bs, or Ec
at 37°C in the absence or presence of antibiotic. (C) Changes in bioreduction activity of HT29 cells on exposure to VCP. The overall concentration of VCP was
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EcDt, and suggests that Bti or Btk BT product-
induced human cell toxicity is not caused by
their PIB-related moieties. In support of this
conclusion, VCP harvested from late Btk
cultures (> 18 hr) reacted to cry1Ab and 1Ac
antibodies, but was 8–10 times less cytotoxic
than VCP harvested from 6- or 8-hr cultures
(35). Therefore it is doubtful that even a sec-
ond generation of δ -endotoxin production
contributes much to the BT product toxiﬁ-
cation so far observed. 
On examining previous studies that used
δ -endotoxin preparations derived from a
variety of mechanical extraction methods, we
observed that no precautions were taken
(reported) to eliminate possible effects from
spores or VCP carryover in δ -endotoxin
preparations before they were tested in vari-
ous systems (10,39,41–43). Furthermore,
these δ -endotoxin preparations were not
derived from commercial BT products. This
is especially important because of the serious
potential for VCP carry-over in batch cul-
tures that would exaggerate the effects
claimed for δ -endotoxins. At present, Bti
PIB cytotoxic effects have been reported for
human erythrocytes, canine kidney fibrob-
lasts (MDCK cells), mouse ﬁbroblasts (L929
cells), primary pig lymphocytes, and mouse
epithelial carcinoma cells (EC2, EC5 and
EC6 cells) (8,10,44,45). Also, PIBs from
noninsecticidal strains of B. thuringiensis
have been shown to be lethal to leukemic T
cells but not to normal T cells (46). These
noncommercial sources were deemed toxic
according to trypan blue uptake by mam-
malian cells (LD50 = 10–80 µg/mL in 30
min) and human erythrocytes (LD50 = 1–2
µg/mL in 60 min), but only if they were pre-
treated at pH 10–10.5 with trypsin (46). In
either case, the morphologic changes (e.g.,
cell rounding, swelling, membrane bleb-
bing, and lysis) were about the same. In our
investigations, an LD50 of approximately
130–140µg/mL was predicated by assays
with PIB δ -endotoxin-related proteins from
Bti and Btk BT product sources. However,
these same effects are caused by VCP from
Bti, Btk, and B. cereus vegetative cells, sug-
gesting that VCP components may have
been included in the culture residues used
to produce PIBs for earlier work. 
VCP effects of Btk, Bti, B. cereus, and
related bacteria. Experiments with vegetative
cells resulting from spore outgrowth demon-
strated that the most toxic substance(s) was
released into the surrounding medium soon
after spores germinated and began proliferat-
ing. Use of VCP instead of BT products, but
at an equivalent dose, reduced the exposure
time seen with BT products by 30-fold or
more. Further study of VCP production is in
order, but we know that it can be generated
in bacterial culture broth as well as in insect
and human cell media, using a range of tem-
peratures from approximately  15°C and up
to 45°C (35). The marked reduction of B.
thuringiensis proliferation in fresh human cell
medium (DMEM) or in medium condi-
tioned by preincubation with human cells
indicates that a direct interaction with
human cells is probably necessary for stimu-
lation of B. thuringiensis growth and possibly
VCP production. Also, low VCP concentra-
tions (Figure 7E) induced an initial stimula-
tion in target cell bioreduction activity.
Because a very similar stimulation was
observed in human and insect cell exposures
to ionophore A23187 (35), the transient
increase in bioreduction could have resulted
from cell membrane alterations allowing an
increased uptake of tetrazolium (MTT) sub-
strate into cells and/or a stimulation of mem-
brane-coupled electron transport at different
intracellular sites (7,47). 
We used strains of spore-forming B.
cereus and B. subtilis and a gram-negative,
nonpathogenic strain of E. coli to investigate
the possibility that the cytotoxic effects pro-
duced by Btk or Bti vegetative cells could also
be produced by other bacteria. The B. cereus
strain is used in standard antibiotic testing
(7). Polymerase chain reaction–DNA
hybridization assays using six different genes
indicated that Bti and Btk spores and this B.
cereus strain share common sequences (13),
whereas B. subtilis is distantly related. The
damage generated from B. cereus in the
absence of antibiotic was remarkably the
same as that seen with Btk and Bti. However,
B. subtilis and E. coli had little or no effect on
target cells in terms of morphology and
capacity for passage without appreciable cell
loss. Also, no toxic effects were observed with
their VCPs (Figure 9C), even after their pro-
tein contents were concentrated to be rough-
ly equivalent to that of VCP from Bti, Btk,
and B.cereus. Unlike B. cereus (and Bti and
Btk), neither B. subtilis nor E. coli grew well
in human culture medium (DMEM), with
or without human cells present. The B. sub-
tilis results are similar to the minimal effects
seen when Vero cells (from kidney of African
green monkey) were treated 2 hr with culture
supernatants from B. subtilis isolated from
Lancashire cotton mills (48). Aside from tar-
get cell binding, the in vitro results with non-
pathogenic E. coli are in contrast to those
from E. coli strains classed as enterohemor-
ragic (e.g., serogroup O157:H7), enteroinva-
sive (029:NM), or enterotoxigenic (C1845),
which showed microvillar destruction (efface-
ment), erythrocyte agglutination, and actin
rearrangements or depolymerization (27,49).
Similar effects were observed when we used
VCP from Btk, Bti, and B. cereus sources and
also when others used 20-fold concentrated
VCP (culture ﬁltrate) of Bacteriodes fragilis
produced in brain–heart infusion medium
for 48 hr at 37°C in 1-hr assays with HT29
(C1 clone line) (33). Also, screening assays
for B.cereus diarrheal enterotoxin with culture
ﬁltrates (VCP) from over 30 isolates revealed
gross morphology changes such as monolayer
disruption and cell shrinkage in assays with
McCoy cells (unknown mouse tissue) and
Vero cells, progressing over a period of 24 hr
(19,50). In a more recent assay involving
Chinese hamster ovary cells to assess toxicity
of 18-hr culture ﬁltrates from several different
Bacillus species, including a putative B.
thuringiensis strain (isolated from cheese and
raw milk), Beattie and Williams (51) showed
a 90% loss in bioreduction activity by 72 hr.
Compared to these earlier assays that used
considerably longer exposure times (overnight
to days), the VCPs from Btk and Bti and also
from the B. cereus strain that we tested were
apparently very toxic. Further side-by-side
experiments are needed to survey the toxic
constituent(s) of various B. cereus strains in
relation to various B. thuringiensis subspecies
and the classical view of B. cereus enterotox-
ins. In related work, we detected enterotoxin
gene sequences in the DNA from spores of all
BT products, and showed that VCP contains
an immunologically related component
which uses two different commercially avail-
able Bacillus enterotoxin test kits (13,35). 
Possible candidates for the B. thuringien-
sis VCP cytotoxin. Compared to δ -endotox-
in work, much less is known about other
toxic substances that may contribute to B.
thuringiensis toxicity, specifically compo-
nents from the fermentation stage of the 
BT production process. Our experiments
demonstrate that the most toxic substance(s)
is a proteinaceous, thermolabile product
common to Bti, Btk, and B. cereus cells. Early
toxic effects included rapid loss in reductive
capacity and protein synthesis. These effects
were reversible only by rapidly replacing the
VCP with fresh medium within the ﬁrst 5
min of exposure; by 10 min of exposure, the
toxic effects resulted in cell detachment, lysis,
and internal protein degradation (35).
Possible candidates considered so far are
ADP-ribosylating toxins, B. cereus-like
enterotoxins, phophatidylinositol-specific
phospholipase C (PI-PLC), and vegetative
insecticidal proteins (52). The 35S-methion-
ine experiments clearly show that an early
step in toxiﬁcation is the cessation of protein
synthesis, which is similar to that seen with
other human (and animal) cells with ADP-
ribosylating toxins of Corynebacterium
diptheria and Vibrio cholera, exotoxin A of
Pseudomonas aeruginosa, Shiga toxin of
Shigella ﬂexnuri, and the Shiga-like toxin of
E. coli (53). These ribosylating toxins transfer
the ADP-ribose moiety to eukaryotic host
target proteins, such as elongation factor 2 α ,
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recent studies indicate that a 45 kDa con-
stituent of the VCP can be covalently labeled
using 32P-NAD as substrate (35), a character-
istic of some ADP-ribosylating toxins. In
other studies we tested B. thuringiensis PI-
PLC and concluded that the lytic effects are
likely the result of another lipase (52). 
Implications for Human
Health 
Before our studies, a handful of case reports
described skin irritation and infections after
spray applications (55–57). The literature also
indicates complications in immunologically
impaired individuals linked to exposure to B.
thuringiensis organisms (15,17,20,55–57).
Further, B. cereus-type ailments can be con-
fused with B. thuringiensis-induced poisoning
because B. thuringiensis is routinely harvested
from common foods such as milk, pasta, and
bread (14,20,57). More recently there has
been a well-documented case report of B.
thuringiensis-mediated soft-tissue infection
and necrosis, along with experimental evi-
dence of pathogenicity, in both immune
compromised and, more importantly, normal
mice (17,18). The results presented here show
for the ﬁrst time that, at the human cell level,
both Bti and Btk BT products can generate
potent B. cereus-like toxic effects. To go
beyond the scale seen in BT product
immunologic sensitization reactions of ﬁeld
workers (3), a sustained infection would be
needed to generate sufﬁcient amounts of veg-
etative cells and their cytolytic exoproducts.
What is lacking is a critical understanding of
conditions that might concern high-risk
groups, those unable to manage microbe inva-
sions through impaired immune responses
and other physical–chemical clearance mecha-
nisms manifested during development (the
very young, the elderly) and in speciﬁc genetic
disorders (e.g., cystic fibrosis). To justify
urban usage of spore-containing BT products,
earlier claims of no health effects need to be
addressed in terms of current medical views
and practices (3,13). This includes testing
health effects of vegetative cell exoproducts
such as CryV (58) and Vip3A (59), which are
proposed for use as novel insecticides.
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scientists and grantees are performing basic studies of our susceptibility to environment-
related disease: demonstrating that a carcinogen in cigarette smoke (benzo(a)pyrene) alters part of a
gene to cause lung cancer . . . showing the effects of fetal exposure to PCBs . . . developing a strain of
mouse that lacks functional estrogen receptors and that helps evaluate how some pesticides and other
estrogen-like compounds might affect development and reproduction . . . discovering the genes for
breast, ovarian, and prostate cancers . . . identifying women’s optimal days of fertility . . . seeking to reverse
the damage from lead exposure . . . ﬁnding alternatives to traditional animal tests . . . pinpointing the
functions of speciﬁc genes by eliminating them from specially bred mouse lines . . . discovering a way, using
ordinary yeast cells, to isolate and clone genes and other fragments of genetic material more quickly . . .
showing the effects of urban air on lung function . . .
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